Published in final edited form as:

Carbohydr Res. 2019 January 15; 472: 115–121. doi:10.1016/j.carres.2018.12.004.

Facile chemoenzymatic synthesis of Lewis a (Le^a) antigen in gram-scale and sialyl Lewis a (sLe^a) antigens containing diverse sialic acid forms

Nova Tasnima^{a,†}, Hai Yu^a, Xuebin Yan^b, Wanqing Li^a, An Xiao^a, and Xi Chen^{a,*}

^aDepartment of Chemistry, University of California, One Shields Avenue, Davis, CA 95616, USA

^bCollege of Chemistry and Molecular Engineering, Zhengzhou University, Zhengzhou, Henan, 450001, China

Abstract

An efficient streamlined chemoenzymatic approach has been developed for gram-scale synthesis of Lewis a antigen ($\text{Le}^a\beta\text{ProN}_3$) and a library of sialyl Lewis a antigens ($\text{sLe}^a\beta\text{ProN}_3$) containing different sialic acid forms. Initially, commercially available inexpensive *N*-acetylglucosamine (GlcNAc) was converted to its *N*'-glycosyl *p*-toluenesulfonylhydrazide in one step. Followed by chemical glycosylation, GlcNAc βProN_3 was synthesized using this protecting group-free method in high yield (82%). Sequential one-pot multienzyme (OPME) β 1–3-galactosylation of GlcNAc βProN_3 followed by OPME α 1–4-fucosylation reactions produced target $\text{Le}^a\beta\text{ProN}_3$ in gram-scale. Structurally diverse sialic acid forms were successfully introduced using a OPME sialylation reaction containing a CMP-sialic acid synthetase and *Pasteurella multocida* α 2–3-sialyltransferase 1 (PmST1) mutant PmST1 M144D with or without a sialic acid aldolase to form $\text{sLe}^a\beta\text{ProN}_3$ containing naturally occurring or non-natural sialic acid forms in preparative scales.

Graphical abstract

Keywords

chemoenzymatic synthesis; glycosyltransferase; Lewis a; sialyl Lewis a; sialic acid; protecting group-free glycosylation

*Corresponding author. Department of Chemistry, University of California-Davis, One Shields Avenue, Davis, CA 95616, USA. Tel.: +1 530 7546037; fax: +1 530 7528995. xiichen@ucdavis.edu (X. Chen).

[†]Current address: Drinking Water and Radiation Laboratory, CA Department of Public Health, 850 Marina Bay Parkway, Richmond, CA 94804, USA

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supporting Information. ¹H and ¹³C NMR spectra of synthesized glycans.

1. Introduction

Lewis a (Le^a) antigen is a blood group antigen found in glycolipids and glycoproteins on the surface of erythrocytes as well as normal glandular and epithelial cells [1, 2]. Its sialylated form, sialyl Lewis a (sLe^a), is expressed on the cells of some normal tissues such as normal fibroblasts, the luminal side of ductal epithelial cells, and some parenchymatous cells [3]. Nevertheless, overexpression of sLe^a has been found on various types of cancer cells with increased levels of fucosylation [4], including colon cancer, pancreatic cancer, gallbladder/bile duct cancer, breast cancer, cholangiocarcinoma, and small cell lung cancer (SCLC) [3, 5, 6]. In fact, sLe^a was named as carbohydrate antigen 19–9 (CA19–9) [7] and was the first reported tumor-associated carbohydrate antigen (TACA) [8]. It was also discovered in the serum of patients with colon or pancreatic cancers [9] and has been used as a serum biomarker of pancreatic cancer [10] and other gastrointestinal cancers in clinic for prognosis determination, postoperative surveillance, and monitoring clinical responses to therapy [4, 7, 11–14]. Nevertheless, false negative and false positive results are possible and precautions are needed in interpreting the data [7, 10, 11].

sLe^a oligosaccharides and analogs have been synthesized chemically [15–20] or chemoenzymatically [21–24]. Chemoenzymatic synthesis of sLe^a antigens by sialidase (e.g. *Salmonella typhimurium* LT2 sialidase)-catalyzed transglycosylation reaction using *p*-nitrophenyl α -*N*-acetylneuraminide (Neu5Ac α pNP) as the glycosyl donor and Le^a trisaccharide as the acceptor was reported but with poor glycosylation yields [25]. All reported glycosyltransferase-catalyzed chemoenzymatic synthesis of sLe^a antigens were carried out using recombinant mammalian enzymes or human milk enzymes including human α 1–4-fucosyltransferase (FucT III) [26, 27] or human milk [28, 29] α 1–3/4-fucosyltransferase, rat liver [22, 23, 26] or porcine submaxillary [28] α 2–3-sialyltransferase, and/or human β 1–3galactosyltransferase [26]. In general, the reactions were carried out by sialyltransferase-catalyzed sialylation of β 1–3-linked galactosides followed by fucosylation in the last step [23]. sLe^a derivatives with variations on the aglycon and the *N*-acyl group on the D-GlcNAc or the LFuc residue have been synthesized. However, modified sialic acid forms have not been introduced to sLe^a although variations at C-5 and C-9 positions of sialic acid have been introduced to sialyl Lewis x (sLe^x) structures [22, 23].

We have been interested in developing an efficient approach for systematically synthesizing sLe^a antigens containing different sialic acid forms which can be used as important probes to understand the structure-function relationship of sLe^a and the important roles of sialic acid modification. Unlike the common glycosylation sequence of sialylation followed by fucosylation for the formation of sLe^a in nature by glycosyltransferase-catalyzed reactions, the most efficient strategy to obtain sLe^a containing different sialic acid forms is to alter the glycosylation sequence by obtaining Le^a followed by α 2–3-sialylation using a suitable α 2–3-sialyltransferase-catalyzed reaction. This strategy will streamline the synthetic scheme and simplify the purification process as demonstrated previously for the synthesis of a library of sialyl Lewis x (sLe^x) antigens containing different sialic acid forms [30]. We show here that Le^a trisaccharide Gal β 1–3(Fuc α 1–4)GlcNAc β ProN₃ can be readily assembled in gram-scale by a bacterial disaccharide phosphorylase-containing one-pot multienzyme (OPME)

galactosylation reaction followed by a bacterial α 1–3/4-fucosyltransferase-containing OPME fucosylation reaction. A previously constructed bacterial α 2–3-sialyltransferase mutant is shown to be efficient in tolerating Le^a as the acceptor substrate to introduce different sialic acid forms with modifications at C-5, C-7, and/or C-9 positions for the synthesis of desired sLe^a antigens in good yields.

2. Results and discussion

2.1 Gram-scale chemoenzymatic synthesis of Le^a antigen Gal β 1–3(Fuc α 1–4)GlcNAc β ProN₃

To synthesize Le^a trisaccharide which could be potentially used as an acceptor substrate for sialyltransferase-catalyzed sialylation reaction for the production of desired sLe^a tetrasaccharides containing different sialic acid forms, monosaccharide glycoside GlcNAc β ProN₃ was chemically synthesized. Comparing different strategies for obtaining the desired compound, a protecting group-free glycosylation strategy using *N*'-glycosyl *p*-toluenesulfonylhydrazides (GSHs) as glycosyl donors reported by Gudmundsdottir and Nitz [31] was identified as an excellent choice. This method was shown to be especially useful for 2-acetamido-sugars such as free *N*-acetylglucosamine (GlcNAc) and unprotected disaccharides containing a free GlcNAc at the reducing end. The reactions resulted in good yields and excellent β -selectivity [32]. The GSH donors can be easily prepared from unprotected sugars and *p*-toluenesulfonyl hydrazide under mild acidic conditions in high yields. They can then be readily activated by *N*-bromosuccinimide (NBS) to couple with various alcohols to form glycosides [31]. We applied this glycosylation method for efficient synthesis of GlcNAc β ProN₃ from commercially available and inexpensive GlcNAc. The azido functional group introduced can be used as a versatile chemical handle for bio-conjugation with alkyne-containing molecules [33]. It can also be readily reduced to an amine for immobilization or conjugation [34, 35].

As shown in Scheme 1, starting from GlcNAc (**1**) and *p*-toluenesulfonyl hydrazide (1.2 equiv.) in the presence of a catalytic amount of acetic acid in dimethylformamide (DMF), the GSH donor (**2**) was synthesized on a multi-gram (26.35 g) scale in a quantitative yield. The product was easily isolated by precipitation using diethyl ether. Glycosylation of 3-chloro-1propanol using the GSH donor (**2**) in the presence of NBS formed glycoside GlcNAc β ProCl which was subsequently converted to the desired GlcNAc β ProN₃ (**3**) by treating with NaN₃ in DMF. Compared to a previously reported method for synthesizing GlcNAc β ProN₃ (**3**) which involved converting GlcNAc to peracetylated GlcNAc trichloroacetimidate followed by glycosylation and deprotection (5 steps, 28% yield) [36, 37], the current route (3 steps, 82% yield) is a much more efficient method which allows easy scaling up.

The obtained GlcNAc β ProN₃ (**3**) was used for gram-scale enzymatic synthesis of disaccharide Gal β 1–3GlcNAc β ProN₃ (**4**) in the presence of galactose (Gal) and adenosine 5' triphosphate (ATP) using a one-pot two-enzyme galactosylation system containing *Streptococcus pneumoniae* (SpGalK) [38] and *Bifidobacterium infantis* D-galactosyl- β 1–3-*N*-acetyl-D-hexosamine phosphorylase (BiGalHexNAcP) [39]. An excellent yield (90%) was achieved after product purification by silica gel column followed by BioGel P-2 gel

filtration column chromatography. Compared to β 1–3-galactosyltransferase-catalyzed reactions, the strategy using BiGalHexNAcP avoided the need to produce uridine 5'-diphosphate-galactose (UDP-Gal) from uridine 5'-triphosphate (UTP). Instead, galactose-1-phosphate formed by galactokinase-catalyzed reaction was directly used for the production of the disaccharide product. In addition, BiGalHexNAcP was able to be expressed at a level of 55 mg/L in *Escherichia coli* culture [39], providing an ample amount of enzyme for large-scale synthesis.

For the synthesis of Le^a trisaccharide from the resulting disaccharide Gal β 1–3GlcNAc β ProN₃ (**4**), a highly efficient fucosyltransferase was needed. We reported recently the cloning and application of a recombinant *Helicobacter pylori* α 1–3/4-fucosyltransferase (Hp3/4FT) in a highly efficient one-pot three-enzyme (OP3E) fucosylation system for the preparative-scale (up to 100 mg) synthesis of diverse α 1–3- and α 1–4-linked fucosides [40]. The Hp3/4FT-containing OP3E fucosylation system was applied for gram scale synthesis of Le^a trisaccharide Gal β 1–3(Fuc α 1–4)GlcNAc β ProN₃ (Le^a β ProN₃, **5**) which was achieved in high-yield (91%) in the presence of L-fucose, adenosine 5'-triphosphate (ATP), and guanosine 5'-triphosphate (GTP). In this system, fucosyltransferase donor substrate guanosine 5'-diphosphate-L-fucose (GDP-Fuc) was generated *in situ* from L-fucose, ATP, and GTP using a bifunctional *Bacteroides fragilis* enzyme (BfFKP) with both L-fucokinase and GDP-Fuc pyrophosphorylase activities [41]. To degrade the by-product pyrophosphate formed in the GDP-fucose formation process to inorganic phosphate, *Pasteurella multocida* inorganic pyrophosphatase (PmPpA) [37] was used. Hp3/4FT-catalyzed fucosylation of disaccharide Gal β 1–3GlcNAc β ProN₃ (**4**) using *in situ* generated GDP-fucose as the donor substrate produced the desired fucoside Le^a β ProN₃ (**5**). The OPME fucosylation approach generated high cost GDP-Fuc *in situ* from inexpensive materials without the purification of intermediates, making the gram-scale synthesis of Le^a an economic and highly efficient process.

2.2 Enzymatic synthesis of sLe^a tetrasaccharides containing different sialic acid forms

The most efficient route for systematic synthesis of sLe^a antigens containing different sialic acid forms would be sialylating Le^a using a one-pot multienzyme (OPME) α 2–3sialylation system [42]. To do this, the sialyltransferase used in the system has to tolerate fucosylated galactosides (e.g. Le^a β ProN₃, **5**) as acceptor substrates. Previously, we reported that a single mutant of *Pasteurella multocida* multifunctional α 2–3sialyltransferase 1 [43], PmST1 M144D, was able to tolerate fucosylated galactoside Le^x β ProN₃ as the acceptor substrates for the synthesis of sLe^x structures containing different sialic acid forms [30]. To our delight, Le^a β ProN₃ (**5**) that differs from Le^x β ProN₃ on both galactosidic and fucosidic linkages was also a suitable acceptor substrate for PmST1 M144D. Therefore, the OPME sialylation system was readily used for the construction of the desired library of sLe^a antigens.

As shown in Scheme 2, the OPME sialylation system containing *Neisseria meningitidis* CMP-sialic acid synthetase (NmCSS) and PmST1 M144D with (A) or without (B) *Pasteurella multocida* sialic acid aldolase (PmNanA), allowed the synthesis of α 2–3-linked sialosides containing diverse sialic acid forms from Le^a β ProN₃ (**5**) and sialic acid precursors with *in situ* generation of a diverse array of CMP-sialic acids. sLe^a β ProN₃ tetrasaccharides

(**6–12**) containing *N*-acetylneuraminic acid (Neu5Ac), *N*-glycolylneuraminic acid (Neu5Gc), 3-deoxy-2-ketonoalosonic acid (Kdn), *N*-trifluoroacetylneuraminic acid (Neu5NTFA), 9-*N*-acetyl-9-deoxyNeu5Ac (Neu5Ac9NAc), 9-*O*-acetyl-Neu5Ac (Neu5,9Ac₂), or 9-*O*-acetyl-Neu5Gc (Neu5Gc9Ac) were successfully synthesized from the corresponding six-carbon (Man/ManNAc derivatives) or 9-carbon (Neu5Ac derivatives) precursors, respectively.

The synthesis of sLe^a tetrasaccharides **6–10** was carried out in the one-pot three-enzyme system at pH 8.5. As shown in Table 1, sLe^aβProN₃ containing naturally occurring sialic acid forms Neu5Acα2–3Le^aβProN₃ (**6**), Neu5Gcα2–3Le^aβProN₃ (**7**), and Kdnα2–3Le^aβProN₃ (**8**) were obtained in 85%, 82%, and 86% yields, respectively, from *N*-acetylmannosamine (ManNAc), *N*-glycolylmannosamine (ManNGc) [44], and mannose (Man) as sialic acid precursors. sLe^aβProN₃ containing non-natural sialic acid forms Neu5NTFAα2–3Le^aβProN₃ (**9**) and Neu5Ac9NAcα2–3Le^aβProN₃ (**10**) were obtained in good yields (80% and 76%, respectively) from C2- or C6-modified ManNAc derivatives *N*-trifluoroacetylmannosamine (ManNTFA) [45] or 6-acetamido-6-deoxy-*N*-acetylmannosamine (ManNAc6NAc) [46, 47], respectively. sLe^aβProN₃ containing naturally occurring 9-*O*-acetylated sialic acid forms Neu5,9Ac₂α2–3Le^aβProN₃ (**11**) and Neu5Gc9Acα2–3Le^aβProN₃ (**12**) were obtained in 62% and 51% yields from Neu5,9Ac₂ and Neu5Gc9Ac [48, 49], respectively, in a one-pot two-enzyme reaction containing NmCSS and PmST1 M144D at pH 7.5. The lower yields for the synthesis of **11** and **12** were due to partial de-*O*-acetylation during the reaction and purification process.

3. Conclusions

In conclusion, an efficient chemoenzymatic method for systematic synthesis of synthetically challenging sialyl Lewis x antigens (sLe^aβProN₃, **6–12**) containing different sialic acid forms was developed successfully. The protecting group-free chemical glycosylation reaction combined with BiGalHexNAcP-catalyzed OPME β1–3-galactosylation and Hp3/4FT-catalyzed OPME fucosylation reactions successfully produced Lewis x antigen (Le^aβProN₃, **5**) in a gram scale. PmST1 M144D was proven to be an efficient catalyst for sialylating Le^a with different sialic acid forms. The study presented here provides a facile chemoenzymatic route for synthesizing Le^a antigen in gram-scale in high yield and for systematic synthesis of sLe^a antigens containing different sialic acid forms.

4. Experimental

4.1. Materials and general methods

Chemicals were purchased and used without further purification. ¹H NMR and ¹³C NMR spectra were recorded on Bruker Avance-800 NMR spectrometer. High resolution electrospray ionization (ESI) mass spectra were obtained using Thermo Electron LTQOrbitrap Hybrid MS at the Mass Spectrometry Facility in the University of California, Davis. Silica gel 60 Å (230–400 mesh, Sorbent Technologies) was used for flash column chromatography. Thin-layer chromatography (Sorbent Technologies) was performed on silica gel plates using *p*-anisaldehyde sugar staining with 5% sulfuric acid in ethanol stain for detection. Gel filtration chromatography was performed with a column (100 cm × 2.5

cm) packed with Bio-Gel P-2 Fine resins (Bio-Rad). Recombinant enzymes *Streptococcus pneumoniae* (SpGalK) [38], *Bifidobacterium infantis* D-galactosyl- β 1-3-*N*-acetyl-Dhexosamine phosphorylase (BiGalHexNAcP) [39], *Bacteroides fragilis* strain NCTC9343 bifunctional L-fucokinase/GDP-fucose pyrophosphorylase (BfFKP) [41], *Pasteurella multocida* inorganic pyrophosphatase [37], *Helicobacter pylori* α 1-3/4-fucosyltransferase (Hp3/4FT) [40], *Pasteurella multocida* sialic acid aldolase (PmNanA) [50], *Neisseria meningitidis* CMP-sialic acid synthetase (NmCSS) [44], and *Pasteurella multocida* α 2-3sialyltransferase 1 M144D mutant (PmST1 M144D) [30] were expressed and purified as described previously.

4.2. Gram-scale synthesis of trisaccharide Le^a β ProN₃ (5)

4.2.1 N'-(2-Acetamido-2-deoxy- β -D-glucopyranosyl)-p-toluenesulfonylhydrazide (2)—GlcNAc (15.0 g, 67.8 mmol) and *p*-toluenesulfonylhydrazide (13.9 g, 74.6 mmol) were dissolved in DMF (30 mL) and H₂O (15 mL), 3 mL of acetic acid was added. The mixture was incubated at 37 °C without stirring for 2 days. After all solids were dissolved, the resulting solution was poured into diethyl ether (1 L) and the mixture was stirred vigorously for overnight. The precipitate was collected to produce compound **2** (26.35 g, 99.8%) as a light yellow solid. ¹H NMR (800 MHz, D₂O) δ 7.71 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 2H), 3.91 (d, *J* = 8.8 Hz, 1H, H-1), 3.86 (dd, *J* = 1.6 and 12.0 Hz, 1H), 3.68 (dd, *J* = 5.6 and 12.0 Hz, 1H), 3.49 (t, *J* = 9.6 Hz, 1H), 3.45 (t, *J* = 9.6 Hz, 1H), 3.34 (t, *J* = 9.6 Hz, 1H), 3.30–3.27 (m, 1H), 2.44 (s, 3H), 2.02 (s, 3H); ¹³C NMR (200 MHz, D₂O) δ 174.10, 145.48, 132.93, 129.85, 129.74, 127.80, 127.68, 89.64 (C-1), 76.50, 74.06, 69.68, 60.63, 53.09, 22.07, 20.63. HRMS (ESI) *m/z* calcd for C₁₅H₂₄N₃O₇S (M+H) 390.1335, found 390.1366.

4.2.2 Synthesis of GlcNAc β ProN₃ (3)—To a solution of compound **2** (2.0 g) in anhydrous DMF (10 mL), 3-chloropropanol (8.6 mL) was added. NBS (2.2 g) was then added at room temperature. After stirring the mixture for 10 minutes, Dowex (OH-) resins were added to quench the reaction. The mixture was stirred until the yellow color disappeared. After filtration, the filtrate was concentrated and purified by flash chromatography (EtOAc: MeOH = 4:1, by volume) to produce 3-chloropropyl GlcNAc as a syrup residue. The obtained product was dissolved in DMF (10 mL) and NaN₃ (1.6 g) was then added. The reaction mixture was stirred at 65 °C for overnight before it was concentrated. The residue was purified by flash chromatography (EtOAc:MeOH = 4:1, by volume) to provide pure GlcNAc β ProN₃ (**3**, 1.28 g, 82%) as a white solid. ¹H NMR (800 MHz, D₂O) δ 4.50 (d, *J* = 8.8 Hz, 1H, H-1), 3.98–3.95 (m, 1H, H-5), 3.92 (dd, *J* = 2.4 and 12.8 Hz, 1H), 3.74 (dd, *J* = 5.6 and 12.8 Hz, 1H), 3.69–3.65 (m, 2H, OCH₂CH₂CH₂N₃), 3.53 (t, *J* = 8.0 Hz, 1H), 3.46–3.41 (m, 2H), 3.40–3.34 (m, 2H, OCH₂CH₂CH₂N₃), 2.04 (s, 3H, NHCOCH₃), 1.86–1.80 (m, 2H, OCH₂CH₂CH₂N₃). ¹³C NMR (200 MHz, D₂O) δ 174.42, 101.06 (C-1), 75.73, 73.63, 69.80, 66.96, 60.61, 55.46, 47.67, 27.99, 22.03. HRMS (ESI) *m/z* calcd for C₁₁H₂₁N₄O₆ (M+H) 305.1461, found 305.1456.

4.2.3 One-pot two-enzyme chemoenzymatic synthesis of Gal β 1-3GlcNAc β ProN₃ (4)—A reaction mixture with 30 mM acceptor GlcNAc β ProN₃ (**3**, 1.04 g, 3.42 mmol), containing Tris-HCl buffer (100 mM, pH 6.55), galactose (1.23 g, 6.84

mmol), ATP (3.77 g, 6.84 mmol), MgCl_2 (20 mM), SpGalK (4.65 mg), and BiGalHexNAcP (5.74 mg) was incubated in a water bath at 37 °C. The reaction progress was monitored by thin-layer chromatography (TLC) and mass spectrometry analyses. When an optimal yield was achieved (after 2 day), the enzyme reaction was terminated by adding same volume of methanol as the reaction mixture and incubating at 4 °C for 30 minutes. The mixture was centrifuged and the precipitates were removed. The supernatant was concentrated and passed through a silica gel column ($\text{EtOAc}:\text{MeOH}:\text{H}_2\text{O} = 6:2:1$, by volume) followed by a Bio-Gel P-2 gel filtration column purification to produce disaccharide $\text{Gal}\beta 1\text{--}3\text{GlcNAc}\beta\text{ProN}_3$ (**4**, 1.43 g, 90%). ^1H NMR (800 MHz, D_2O) δ 4.53 (d, $J = 8.0$ Hz, 1H, $\text{H}_{\text{GlcNAc-1}}$), 4.41 (d, $J = 8.0$ Hz, 1H, $\text{H}_{\text{Gal-1}}$), 3.97–3.88 (m, 3H), 3.81 (t, $J = 10.4$ Hz, 1H), 3.78–3.61 (m, 7H), 3.52 (t, $J = 10.4$ Hz, 1H), 3.51–3.45 (m, 2H), 3.38–3.28 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{N}_3$), 2.02 (s, 3H, NHCOCH_3), 1.84–1.81 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{N}_3$); ^{13}C NMR (200 MHz, D_2O) δ 174.46, 103.40 ($\text{C}_{\text{Gal-1}}$), 100.80 ($\text{C}_{\text{GlcNAc-1}}$), 82.25, 75.22, 75.14, 72.34, 70.53, 68.58, 68.39, 67.03, 60.89, 60.58, 54.44, 47.65, 27.97, 22.09. HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{31}\text{N}_4\text{O}_{11}$ ($\text{M}+\text{H}$) 467.1989, found 467.1986.

4.2.4 One-pot three-enzyme chemoenzymatic synthesis of $\text{Le}^a\beta\text{ProN}_3$ (5**)**—A reaction mixture containing Tris-HCl buffer (100 mM, pH 7.5), $\text{Gal}\beta 1\text{--}3\text{GlcNAc}\beta\text{ProN}_3$ (**4**, 1.18 g, 30 mM, 2.53 mmol), L-fucose (0.62 g, 3.80 mmol), ATP (2.10 g, 3.80 mmol), GTP (2.15 g, 3.80 mmol), MgCl_2 (20 mM), BfFKP (4.49 mg), PmPpA (1.35 mg), and Hp3/4FT (10.55 mg) was incubated in a water bath at 37 °C. The reaction was monitored by TLC and mass spectrometry analyses. When an optimal yield was achieved (after 2 days), the same volume (115 mL) of methanol was added to the reaction mixture. This mixture was incubated at 4 °C for 30 min and then centrifuged. The supernatant was concentrated and passed through a silica gel column ($\text{EtOAc}:\text{MeOH}:\text{H}_2\text{O} = 5:2:1$, by volume) followed by a Bio-Gel P-2 gel filtration column purification to produce $\text{Le}^a\beta\text{ProN}_3$ (**5**, 1.41 g, 91%) as a white powder. ^1H NMR (800 MHz, D_2O) δ 5.01 (d, $J = 4.0$ Hz, 1H, $\text{H}_{\text{Fuc-1}}$), 4.88–4.85 (m, 1H, $\text{H}_{\text{Fuc-5}}$), 4.52 (d, $J = 8.8$ Hz, 1H, $\text{H}_{\text{GlcNAc-1}}$), 4.48 (d, $J = 8.0$ Hz, 1H, $\text{H}_{\text{Gal-1}}$), 4.07–3.34 (m, 19H), 2.04 (s, 3H, NHCOCH_3), 1.86–1.82 (m, 2H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{N}_3$), 1.17 (d, $J = 6.4$ Hz, 3H, $\text{H}_{\text{Fuc-6}}$); ^{13}C NMR (200 MHz, D_2O) δ 174.24, 102.77 ($\text{C}_{\text{Gal-1}}$), 100.93 ($\text{C}_{\text{GlcNAc-1}}$), 97.96 ($\text{C}_{\text{Fuc-1}}$), 75.96, 75.29, 74.70, 72.31, 72.18, 71.83, 70.35, 69.01, 68.24, 67.66, 67.08, 66.75, 61.55, 59.57, 55.65, 47.66, 28.01, 22.16, 15.25. HRMS (ESI) m/z calculated for $\text{C}_{23}\text{H}_{40}\text{N}_4\text{NaO}_{15}$ ($\text{M}+\text{Na}$) 635.2388, found 635.2353.

4.3. General procedure of one-pot multienzyme synthesis of sLe^a containing different sialic acid forms (**6–12**):

$\text{Le}^a\beta\text{ProN}_3$ (**5**, 10–15 mM, 1 equiv.), a sialic acid precursor (mannose, ManNAc, or their derivatives, 1.5 equiv.), sodium pyruvate (5–7.5 equiv. when six-carbon sugars used as substrates), CTP (1.3–2.0 equiv.) were dissolved in water in a 50 mL centrifugal tube. The pH of this mixture was adjusted to neutral. MgCl_2 (20 mM) and Tris-HCl buffer (100 mM, pH 8.5 for reactions using ManNAc, Man, or derivatives as the sialyltransferase donor precursor; or pH 7.5 for reactions using Neu5,9Ac₂ or Neu5Gc9Ac as the sialyltransferase donor precursor) were then added. After adding NmCSS (1–3 mg) and PmST1 M144D (1–3.5 mg) with (1–3 mg, for reactions using ManNAc, Man, or derivatives as the sialyltransferase donor precursor) or without PmNanA, water was added to bring the

concentration of the acceptor to the range of 10–15 mM. The reactions were carried out for 12–36 hours before they were stopped by adding the same volume of ice-cold methanol followed by incubation at 4 °C for 30 min. After centrifugation, the supernatant was concentrated and purified by a BioGel P-2 gel filtration column chromatography with or without an additional C18-column chromatography in a high-performance liquid chromatography (HPLC) system to obtain the desired products.

4.3.1. Neu5Ac α 2–3Le a β ProN $_3$ (6),—203 mg, 85% yield, white powder: ^1H NMR (800 MHz, D $_2$ O) δ 5.00 (d, J = 4.0 Hz, 1H, H $_{\text{Fuc-1}}$), 4.88–4.84 (m, 1H, H $_{\text{Fuc-5}}$), 4.52 (d, J = 8.0 Hz, 2H, H $_{\text{Gal-1}}$ and H $_{\text{GlcNAc-1}}$), 4.06 (t, J = 9.6 Hz, 1H), 4.04 (dd, J = 3.2 and 9.6 Hz, 1H), 3.98–3.94 (m, 2H), 3.89 (d, J = 3.2 Hz, 1H), 3.88–3.51 (m, 18H), 3.49 (t, J = 8.0 Hz, 1H), 3.40–3.34 (m, 2H, OCH $_2$ CH $_2$ CH $_2$ N $_3$), 2.76 (dd, J = 4.8 and 12.8 Hz, 1H, H $_{\text{Neu5Ac}_{\text{eq-3}}}$), 2.04 (s, 3H, NHCOCH $_3$), 2.02 (s, 3H, NHCOCH $_3$), 1.85–1.81 (m, 2H, OCH $_2$ CH $_2$ CH $_2$ N $_3$), 1.76 (t, J = 12.0 Hz, 1H, H $_{\text{Neu5Ac}_{\text{ax-3}}}$), 1.16 (d, J = 6.4 Hz, 3H, H $_{\text{Fuc-6}}$); ^{13}C NMR (200 MHz, D $_2$ O) δ 174.81, 174.11, 173.81, 102.68 (C $_{\text{Gal-1}}$), 100.86 (C $_{\text{GlcNAc-1}}$), 99.24 (C $_{\text{Neu5Ac-2}}$), 97.93 (C $_{\text{Fuc-1}}$), 75.93, 75.48, 75.33, 74.63, 72.62, 72.22, 71.82, 71.74, 68.97, 68.66, 68.31, 67.90, 67.66, 67.07, 66.80, 66.72, 62.17, 61.55, 59.58, 51.55, 47.66, 39.89, 28.00, 22.29, 21.92, 15.21, HRMS (ESI) m/z calculated for C $_{34}$ H $_{57}$ N $_5$ O $_{23}$ (M-H) 902.3372, found 902.3366.

4.3.2. Neu5Gc α 2–3Le a β ProN $_3$ (7),—37 mg, 82% yield, white powder: ^1H NMR (800 MHz, D $_2$ O) δ 5.00 (d, J = 4.0 Hz, 1H, H $_{\text{Fuc-1}}$), 4.88–4.85 (m, 1H, H $_{\text{Fuc-2}}$), 4.53 (d, J = 8.0 Hz, 2H, H $_{\text{Gal-1}}$ and H $_{\text{GlcNAc-1}}$), 4.11 (s, 2H, NHCOCH $_2$ OH), 4.08–4.04 (m, 2H), 3.98–3.95 (m, 2H), 3.93 (t, J = 10.4 Hz, 1H), 3.91 (d, J = 3.2 Hz, 1H), 3.89–3.52 (m, 17H), 3.50 (t, J = 8.0 Hz, 1H), 3.40–3.34 (m, 2H, OCH $_2$ CH $_2$ CH $_2$ N $_3$), 2.78 (dd, J = 4.8 and 12.8 Hz, 1H, H $_{\text{Neu5Ac}_{\text{eq-3}}}$), 2.05 (s, 3H, NHCOCH $_3$), 1.86–1.82 (m, 2H, OCH $_2$ CH $_2$ CH $_2$ N $_3$), 1.78 (t, J = 12.8 Hz, 1H, H $_{\text{Neu5Ac}_{\text{ax-3}}}$), 1.17 (d, J = 6.4 Hz, 3H, H $_{\text{Fuc-6}}$); ^{13}C NMR (200 MHz, D $_2$ O) δ 175.58, 174.11, 173.85, 102.70 (C $_{\text{Gal-1}}$), 100.87 (C $_{\text{GlcNAc-1}}$), 99.25 (C $_{\text{Neu5Ac-2}}$), 97.94 (C $_{\text{Fuc-1}}$), 75.94, 75.47, 75.34, 74.64, 72.35, 72.22, 71.82, 68.98, 68.67, 68.04, 67.84, 67.67, 67.07, 66.79, 66.73, 62.14, 61.56, 60.86, 59.58, 55.60, 51.26, 47.66, 39.98, 28.01, 22.30, 15.22. HRMS (ESI) m/z calculated for C $_{34}$ H $_{57}$ N $_5$ O $_{24}$ (M-H) 918.3321, found 918.3300.

4.3.3. Kd α 2–3Le a β ProN $_3$ (8),—122 mg, 86% yield, white powder: ^1H NMR (800 MHz, D $_2$ O) δ 4.99 (d, J = 4.0 Hz, 1H, H $_{\text{Fuc-1}}$), 4.87–4.84 (m, 1H, H $_{\text{Fuc-5}}$), 4.51 (d, J = 7.2 Hz, 2H, H $_{\text{Gal-1}}$ and H $_{\text{GlcNAc-1}}$), 4.04 (t, J = 9.9 Hz, 1H), 4.02 (dd, J = 3.2 and 10.4 Hz, 1H), 3.98–3.51 (m, 21H), 3.48 (t, J = 8.0 Hz, 1H), 3.40–3.34 (m, 2H, OCH $_2$ CH $_2$ CH $_2$ N $_3$), 2.71 (dd, J = 4.8 and 12.8 Hz, 1H, H $_{\text{Neu5Ac}_{\text{eq-3}}}$), 2.05 (s, 3H, NHCOCH $_3$), 1.85–1.81 (m, 2H, OCH $_2$ CH $_2$ CH $_2$ N $_3$), 1.70 (t, J = 12.0 Hz, 1H, H $_{\text{Neu5Ac}_{\text{ax-3}}}$), 1.15 (d, J = 6.4 Hz, 3H, H $_{\text{Fuc-6}}$); ^{13}C NMR (200 MHz, D $_2$ O) δ 174.09, 173.98, 102.74 (C $_{\text{Gal-1}}$), 100.88 (C $_{\text{GlcNAc-1}}$), 99.10 (C $_{\text{Neu5Ac-2}}$), 97.94 (C $_{\text{Fuc-1}}$), 75.97, 75.38, 75.32, 74.64, 73.65, 72.21, 72.04, 71.82, 70.15, 69.61, 68.97, 68.64, 67.66, 67.56, 67.07, 66.72, 66.69, 62.22, 61.56, 59.56, 55.57, 47.66, 39.62, 28.00, 22.29, 15.21. HRMS (ESI) m/z calculated for C $_{32}$ H $_{54}$ N $_4$ O $_{23}$ (M-H) 861.3106, found 861.3115.

4.3.4. Neu5NTFA α 2-3Le α β ProN₃ (9),—64 mg, 80% yield, white powder: ¹H NMR (800 MHz, D₂O) δ 5.00 (d, J = 4.0 Hz, 1H, H_{Fuc}-1), 4.88–4.85 (m, 1H, H_{Fuc}-5), 4.52 (d, J = 8.0 Hz, 1H, H_{GlcNAc}-1), 4.51 (d, J = 8.0 Hz, 1H, H_{Gal}-1), 4.06–4.04 (m, 2H), 4.00 (t, J = 9.6 Hz, 1H), 3.98–3.94 (m, 2H), 3.90 (d, J = 3.2 Hz, 1H), 3.88–3.51 (m, 17H), 3.50 (t, J = 8.0 Hz, 1H), 3.39–3.34 (m, 2H, OCH₂CH₂CH₂N₃), 2.79 (dd, J = 4.8 and 12.8 Hz, 1H, H_{Neu5Ac_{eq}}-3), 2.04 (s, 3H, NHCOCH₃), 1.85–1.81 (m, 2H, OCH₂CH₂CH₂N₃), 1.78 (t, J = 12.8 Hz, 1H, H_{Neu5Ac_{ax}}-3), 1.16 (d, J = 6.4 Hz, 3H, H_{Fuc}-6); ¹³C NMR (200 MHz, D₂O) δ 174.11, 173.71, 102.71 (C_{Gal}-1), 100.88 (C_{GlcNAc}-1), 99.22 (C_{Neu5Ac}-2), 97.94 (C_{Fuc}-1), 75.98, 75.43, 75.33, 74.62, 72.21, 71.93, 71.82, 68.97, 68.64, 67.96, 67.84, 67.66, 67.07, 66.72, 62.11, 61.55, 59.57, 52.10, 47.66, 39.97, 28.00, 22.29, 15.21. HRMS (ESI) m/z calculated for C₃₄H₅₃F₃N₅O₂₃ (M-H) 956.3089, found 956.3084.

4.3.5. Neu5Ac9NAc α 2-3Le α β ProN₃ (10),—35 mg, 76% yield, white powder: ¹H NMR (800 MHz, D₂O) δ 5.00 (d, J = 4.0 Hz, 1H, H_{Fuc}-1), 4.88–4.83 (m, 1H, H_{Fuc}-5), 4.54–4.47 (m, 2H, H_{Gal}-1 and H_{GlcNAc}-1), 4.06 (t, J = 9.6 Hz, 1H), 4.01 (dd, J = 3.2 and 9.6 Hz, 1H), 3.98–3.95 (m, 2H), 3.90 (d, J = 3.2 Hz, 1H), 3.88–3.47 (m, 18H), 3.40–3.34 (m, 2H, OCH₂CH₂CH₂N₃), 3.25 (dd, J = 8.0 and 14.4 Hz, 1H), 2.76 (dd, J = 4.8 and 12.8 Hz, 1H, H_{Neu5Ac_{eq}}-3), 2.02 (s, 3H, NHCOCH₃), 2.01 (s, 6H, 2xNHCOCH₃), 1.87–1.80 (m, 2H, OCH₂CH₂CH₂N₃), 1.77 (t, J = 12.0 Hz, 1H, H_{Neu5Ac_{ax}}-3), 1.16 (d, J = 6.4 Hz, 3H, H_{Fuc}-6); ¹³C NMR (200 MHz, D₂O) δ 174.75, 174.19, 173.92, 173.80, 102.62 (C_{Gal}-1), 100.86 (C_{GlcNAc}-1), 99.47 (C_{Neu5Ac}-2), 97.93 (C_{Fuc}-1), 75.94, 75.57, 75.33, 74.63, 72.50, 72.22, 71.82, 69.89, 69.45, 68.98, 68.66, 68.27, 67.67, 67.04, 66.88, 66.73, 61.55, 59.59, 55.60, 51.55, 47.66, 41.92, 39.84, 28.01, 22.18, 21.93, 21.66, 15.21. HRMS (ESI) m/z calculated for C₃₆H₆₀N₆O₂₃ (M-H) 943.3637, found 943.3641.

4.3.6. Neu5,9Ac α 2-3Le α β ProN₃ (11),—29 mg, 62% yield, white powder: ¹H NMR (800 MHz, D₂O) δ 5.00 (d, J = 3.2 Hz, 1H, H_{Fuc}-1), 4.87–4.84 (m, 1H, H_{Fuc}-5), 4.53 (d, J = 8.0 Hz, 2H, H_{Gal}-1 and H_{GlcNAc}-1), 4.38 (dd, J = 2.4 and 11.2 Hz, 1H), 4.18 (dd, J = 7.2 and 12.0 Hz, 1H), 4.083.52 (m, 21H), 3.51 (t, J = 8.0 and 14.4 Hz, 1H), 3.41–3.34 (m, 2H, OCH₂CH₂CH₂N₃), 2.76 (dd, J = 4.8 and 12.8 Hz, 1H, H_{Neu5Ac_{eq}}-3), 2.13 (s, 3H, OCOCH₃), 2.04 (s, 3H, NHCOCH₃), 2.03 (s, 3H, NHCOCH₃), 1.87–1.80 (m, 3H, OCH₂CH₂CH₂N₃ and H_{Neu5Ac_{ax}}-3), 1.17 (d, J = 7.2 Hz, 3H, H_{Fuc}-6); ¹³C NMR (200 MHz, D₂O) δ 174.76, 174.17, 174.01, 172.66, 102.64 (C_{Gal}-1), 100.85 (C_{GlcNAc}-1), 98.61 (C_{Neu5Ac}-2), 97.92 (C_{Fuc}-1), 75.98, 75.39, 75.34, 74.50, 72.55, 72.20, 71.83, 69.08, 69.00, 68.68, 68.12, 67.85, 67.67, 67.06, 66.74, 66.72, 65.77, 61.44, 59.59, 51.52, 47.67, 39.47, 28.01, 22.27, 21.97, 20.16, 15.21. HRMS (ESI) m/z calculated for C₃₆H₅₈N₅O₂₄ (M-H) 944.3477, found 944.3430.

4.3.7. Neu5Gc9Aca α 2-3Le α β ProN₃ (12),—12 mg, 51% yield, white powder: ¹H NMR (800 MHz, D₂O) δ 5.00 (d, J = 4.0 Hz, 1H, H_{Fuc}-1), 4.88–4.85 (m, 1H, H_{Fuc}-2), 4.53 (d, J = 8.0 Hz, 1H, H_{GlcNAc}-1), 4.52 (d, J = 8.0 Hz, 1H, H_{Gal}-1), 4.35 (dd, J = 2.4 and 11.2 Hz, 1H), 4.18 (dd, J = 6.4 and 12.0 Hz, 1H), 4.11 (s, 2H, OCH₂OCOCH₃), 4.07–3.51 (m, 21H), 3.50 (t, J = 8.0 and 14.4 Hz, 1H), 3.40–3.34 (m, 2H, OCH₂CH₂CH₂N₃), 2.78 (dd, J = 4.8 and 12.8 Hz, 1H, H_{Neu5Ac_{eq}}-3), 2.13 (s, 3H, OCOCH₃), 2.04 (s, 3H, NHCOCH₃), 1.85–1.81 (m, 2H, OCH₂CH₂CH₂N₃), 1.78 (t, J = 12.0 Hz, 1H, H_{Neu5Ac_{ax}}-3), 1.16 (d, J = 6.4 Hz, 3H,

H_{Fuc}-6); ¹³C NMR (200 MHz, D₂O) δ 175.53, 174.25, 174.17, 173.99, 102.77(C_{Gal}-1), 102.69(C_{GlcNAc}-1), 100.87(C_{Neu5Ac}-1), 97.94(C_{Fuc}-1), 76.00, 75.40, 75.35, 75.30, 74.71, 74.54, 72.32, 72.22, 71.83, 70.36, 69.26, 69.00, 68.68, 68.24, 68.05, 67.67, 67.07, 66.73, 65.67, 61.55, 61.49, 60.88, 59.59, 55.59, 51.20, 47.67, 39.70, 28.01, 22.28, 22.16, 20.17, 15.25, 15.21. HRMS (ESI) m/z calculated for C₃₆H₅₈N₅O₂₅ (M-H) 960.3426, found 960.3420.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

This work was supported by the United States National Institutes of Health under Award Numbers U01GM120419 and R01AI130684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the United States National Institutes of Health. The Bruker Avance-800 NMR spectrometer was funded by the United States National Science Foundation grant DBIO-722538.

Reference

- [1]. Blaszczyk M, Pak KY, Herlyn M, Sears HF, Steplewski Z, Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas, Proc. Natl. Acad. Sci. U. S. A 82 (1985) 3552–3556. [PubMed: 2582419]
- [2]. Green C, The ABO, Lewis and related blood group antigens; a review of structure and biosynthesis, FEMS Microbiol. Immunol 1 (1989) 321–330. [PubMed: 2698728]
- [3]. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO, Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens, Int. J. Cancer 73 (1997) 50–56. [PubMed: 9334809]
- [4]. Blanas A, Sahasrabudhe NM, Rodriguez E, van Kooyk Y, van Vliet SJ, Fucosylated antigens in cancer: An alliance toward tumor progression, metastasis, and resistance to chemotherapy, Front. Oncol 8 (2018) 39. [PubMed: 29527514]
- [5]. Ugorski M, Laskowska A, Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells, Acta Biochim. Pol 49 (2002) 303–311. [PubMed: 12362971]
- [6]. Narita T, Funahashi H, Satoh Y, Watanabe T, Sakamoto J, Takagi H, Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer, Cancer 71 (1993) 3044–3053. [PubMed: 8490832]
- [7]. Scara S, Bottoni P, Scatena R, CA 19–9: Biochemical and clinical aspects, Adv. Exp. Med. Biol 867 (2015) 247–260. [PubMed: 26530370]
- [8]. Gong E, Hirohashi S, Shimosato Y, Expression of carbohydrate antigen 19–9 and stage-specific embryonic antigen 1 in non-tumorous and tumorous epithelia of the human colon and rectum, J. Natl. Cancer Inst 75 (1985) 447–454. [PubMed: 2863413]
- [9]. Koprowski H, Herlyn M, Steplewski Z, Sears HF, Specific antigen in serum of patients with colon carcinoma, Science 212 (1981) 53–55. [PubMed: 6163212]
- [10]. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V, Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report, Ann. Oncol 21 (2010) 441–447. [PubMed: 19690057]
- [11]. Galli C, Basso D, Plebani M, CA 19–9: handle with care, Clin. Chem. Lab. Med 51 (2013) 1369–1383. [PubMed: 23370912]
- [12]. Trinchera M, Aronica A, Dall'Olio F, Selectin ligands sialyl-Lewis a and sialylLewis x in gastrointestinal cancers, Biology (Basel) 6 (2017).
- [13]. Reis CA, Osorio H, Silva L, Gomes C, David L, Alterations in glycosylation as biomarkers for cancer detection, J. Clin. Pathol 63 (2010) 322–329. [PubMed: 20354203]

- [14]. Pinho SS, Reis CA, Glycosylation in cancer: mechanisms and clinical implications, *Nat. Rev. Cancer* 15 (2015) 540–555. [PubMed: 26289314]
- [15]. Peilstöcker K, Kunz H, A sialyl-Lewis a-asparagine building block for glycopeptide-synthesis, *Synlett* (2000) 820–822.
- [16]. Ragupathi G, Damani P, Srivastava G, Srivastava O, Sucheck SJ, Ichikawa Y, Livingston PO, Synthesis of sialyl Lewis(a) (sLe^a), CA19–9 and construction of an immunogenic sLe(a) vaccine, *Cancer Immunol. Immunother* 58 (2009) 13971405.
- [17]. Toepfer A, Schmidt RR, An efficient synthesis of the Lewis A (Le^a) antigen pentasaccharide moiety, *J. Carbohydr. Chem* 12 (1993) 809–822.
- [18]. Manzoni L, Castelli R, Synthesis of the Lewis a trisaccharide based on an anomeric silyl fluoros tag, *Org. Lett* 6 (2004) 4195–4198. [PubMed: 15524441]
- [19]. Kobayashi D, Ueki A, Yamaji T, Nagao K, Imamura A, Ando H, Kiso M, Ishida H, Efficient synthesis of the Lewis a tandem repeat, *Molecules (Basel, Switzerland)* 21 (2016) pii: E614.
- [20]. Kiso M, Furui H, Ando K, Ishida H, Hasegawa A, Systematic synthesis of *N*-methyl-1-deoxynojirimycin-containing, Le(x), Le(a), sialyl-Le(x) and sialyl-Le(a) epitopes recognized by selectins, *Bioorg. Med. Chem* 2 (1994) 1295–1308. [PubMed: 7538870]
- [21]. Palcic MM, Venot AP, Ratcliffe RM, Hindsgaul O, Enzymic synthesis of oligosaccharides terminating in the tumor-associated sialyl-Lewis-a determinant, *Carbohydr. Res* 190 (1989) 1–11. [PubMed: 2790838]
- [22]. Baisch G, Ohrlein R, Glycosyltransferase catalyzed assemblage of sialyl-Lewis(a)saccharopeptides, *Carbohydr. Res* 312 (1998) 61–72. [PubMed: 9836451]
- [23]. Ernst B, Ohrlein R, Substrate and donor specificity of glycosyl transferases, *Glycoconj. J* 16 (1999) 161–170. [PubMed: 10612415]
- [24]. Barstrom M, Bengtsson M, Blixt O, Norberg T, New derivatives of reducing oligosaccharides and their use in enzymatic reactions: efficient synthesis of sialyl Lewis a and sialyl dimeric Lewis x glycoconjugates, *Carbohydr. Res* 328 (2000) 525–531. [PubMed: 11093708]
- [25]. Makimura Y, Ishida H, Kondo A, Hasegawa A, Kiso M, Regioselective $\alpha(2\rightarrow3)$ sialylation of Le^X and Le^a by sialidase-catalyzed transglycosylation, *J. Carbohydr. Chem* 17 (1998) 975–979.
- [26]. Baisch G, Ohrlein R, Streiff M, Kolbinger F, On the preparative use of recombinant beta(1–3)galactosyl-transferase, *Bioorg. Med. Chem. Lett* 8 (1998) 751754.
- [27]. Baisch G, Ohrlein R, Streiff M, Kolbinger F, Enzymatic synthesis of sialylLewis(a)-libraries with two non-natural monosaccharide units, *Bioorg. Med. Chem. Lett* 8 (1998) 755–758. [PubMed: 9871536]
- [28]. Palcic MM, Venot AP, Ratcliffe RM, Hindsgaul O, Enzymic synthesis of oligosaccharides terminating in the tumor-associated sialyl-Lewis-a determinant, *Carbohydr. Res* 190 (1989) 1–11. [PubMed: 2790838]
- [29]. Nikrad PV, Kashem MA, Wlasichuk KB, Alton G, Venot AP, Use of humanmilk fucosyltransferase in the chemoenzymic synthesis of analogues of the sialyl Lewis(a) and sialyl Lewis(x) tetrasaccharides modified at the C-2 position of the reducing unit, *Carbohydr. Res* 250 (1993) 145–160. [PubMed: 8143288]
- [30]. Sugiarto G, Lau K, Qu J, Li Y, Lim S, Mu S, Ames JB, Fisher AJ, Chen X, A sialyltransferase mutant with decreased donor hydrolysis and reduced sialidase activities for directly sialylating Lewis^X, *ACS Chem. Biol* 7 (2012) 1232–1240. [PubMed: 22583967]
- [31]. Gudmundsdottir AV, Nitz M, Protecting group free glycosidations using ptoluenesulfonohydrazide donors, *Org. Lett* 10 (2008) 3461–3463. [PubMed: 18616337]
- [32]. Hernandez Armada D, Santos JT, Richards MR, Cairo CW, Protecting groupfree immobilization of glycans for affinity chromatography using glycosylsulfonohydrazide donors, *Carbohydr. Res* 417 (2015) 109–116. [PubMed: 26454791]
- [33]. Tiwari VK, Mishra BB, Mishra KB, Mishra N, Singh AS, Chen X, Cu-catalyzed click reaction in carbohydrate chemistry. *Chem. Rev* 116 (2016) 3086–3240. [PubMed: 26796328]
- [34]. Deng L, Chen X, Varki A, Exploration of sialic acid diversity and biology using sialoglycan microarrays. *Biopolymers* 99 (2013) 650–665. [PubMed: 23765393]

- [35]. Chokhawala HA, Huang S, Lau K, Yu H, Cheng J, Thon V, Hurtado-Ziola N, Guerrero JA, Varki A, Chen X, Combinatorial chemoenzymatic synthesis and high-throughput screening of sialosides. *ACS Chem. Biol* 3 (2008) 567–576. [PubMed: 18729452]
- [36]. Sudibya HG, Ma J, Dong X, Ng S, Li L-J, Liu X-W, Chen P, Interfacing glycosylated carbon-nanotube-network devices with living cells to detect dynamic secretion of biomolecules, *Angew. Chem. Int. Ed* 48 (2009) 2723–2726.
- [37]. Lau K, Thon V, Yu H, Ding L, Chen Y, Muthana MM, Wong D, Huang R, Chen X, Highly efficient chemoenzymatic synthesis of beta1–4-linked galactosides with promiscuous bacterial beta1–4-galactosyltransferases, *Chem. Commun* 46 (2010) 6066–6068.
- [38]. Chen M, Chen LL, Zou Y, Xue M, Liang M, Jin L, Guan WY, Shen J, Wang W, Wang L, Liu J, Wang PG, Wide sugar substrate specificity of galactokinase from *Streptococcus pneumoniae* TIGR4, *Carbohydr. Res* 346 (2011) 2421–2425. [PubMed: 21903203]
- [39]. Yu H, Thon V, Lau K, Cai L, Chen Y, Mu S, Li Y, Wang PG, Chen X, Highly efficient chemoenzymatic synthesis of beta1–3-linked galactosides, *Chem. Commun* 46 (2010) 7507–7509.
- [40]. Yu H, Li Y, Wu Z, Li L, Zeng J, Zhao C, Wu Y, Tasnima N, Wang J, Liu H, Gadi MR, Guan W, Wang PG, Chen X, *H. pylori* alpha1–3/4-fucosyltransferase (Hp3/4FT)-catalyzed one-pot multienzyme (OPME) synthesis of Lewis antigens and human milk fucosides, *Chem. Commun* 53 (2017) 11012–11015.
- [41]. Yi W, Liu X, Li Y, Li J, Xia C, Zhou G, Zhang W, Zhao W, Chen X, Wang PG, Remodeling bacterial polysaccharides by metabolic pathway engineering, *Proc. Natl. Acad. Sci. U. S. A* 106 (2009) 4207–4212. [PubMed: 19251666]
- [42]. Yu H, Chokhawala HA, Huang S, Chen X, One-pot three-enzyme chemoenzymatic approach to the synthesis of sialosides containing natural and nonnatural functionalities, *Nat. Protoc* 1 (2006) 2485–2492. [PubMed: 17406495]
- [43]. Yu H, Chokhawala H, Karpel R, Yu H, Wu B, Zhang J, Zhang Y, Jia Q, Chen X, A multifunctional *Pasteurella multocida* sialyltransferase: a powerful tool for the synthesis of sialoside libraries, *J. Am. Chem. Soc* 127 (2005) 17618–17619. [PubMed: 16351087]
- [44]. Yu H, Yu H, Karpel R, Chen X, Chemoenzymatic synthesis of CMP-sialic acid derivatives by a one-pot two-enzyme system: comparison of substrate flexibility of three microbial CMP-sialic acid synthetases, *Bioorg. Med. Chem* 12 (2004) 64276435.
- [45]. Humphrey AJ, Fremann C, Critchley P, Malykh Y, Schauer R, Bugg TD, Biological properties of *N*-acetyl and *N*-haloacetyl neuraminic acids: processing by enzymes of sialic acid metabolism, and interaction with influenza virus, *Bioorg. Med. Chem* 10 (2002) 3175–3185. [PubMed: 12150863]
- [46]. Khedri Z, Xiao A, Yu H, Landig CS, Li W, Diaz S, Wasik BR, Parrish CR, Wang L-P, Varki A, Chen X, A chemical biology solution to problems with studying biologically important but unstable 9-*O*-acetyl sialic acids, *ACS Chem. Biol* 12 (2017) 214–224. [PubMed: 27936566]
- [47]. Li W, Xiao A, Li Y, Yu H, Chen X, Chemoenzymatic synthesis of Neu5Ac9NAcontaining alpha2–3- and alpha2–6-linked sialosides and their use for sialidase substrate specificity studies, *Carbohydr. Res* 451 (2017) 51–58. [PubMed: 28961426]
- [48]. Yu H, Cheng J, Ding L, Khedri Z, Chen Y, Chin S, Lau K, Tiwari VK, Chen X, Chemoenzymatic synthesis of GD3 oligosaccharides and other disialyl glycans containing natural and non-natural sialic acids, *J. Am. Chem. Soc* 131 (2009) 18467–18477. [PubMed: 19947630]
- [49]. Ogura H, Furuhashi K, Sato S, Anazawa K, Itoh M, Shitori Y, Synthesis of 9-*O*-acetyl- and 4-*O*-acetyl-sialic acids, *Carbohydr. Res* 167 (1987) 77–86. [PubMed: 3690578]
- [50]. Li Y, Yu H, Cao H, Lau K, Muthana S, Tiwari VK, Son B, Chen X, *Pasteurella multocida* sialic acid aldolase: a promising biocatalyst, *Appl. Microbiol. Biotechnol* 79 (2008) 963–970. [PubMed: 18521592]

Highlights:

- High-yield protection group-free glycosylation for synthesizing GlcNAc β ProN₃
- Gram-scale chemoenzymatic synthesis of Lewis a antigen was efficiently achieved
- Le^a β ProN₃ was shown to be a suitable acceptor for PmST1 M144D
- Seven sLe^a antigens containing different sialic acid forms were synthesized
- A high-yield chemoenzymatic method for Le^a and sLe^a synthesis was demonstrated

Scheme 1.

Gram-scale chemoenzymatic synthesis of Le^aβProN₃ (**5**). Enzyme abbreviations: SpGalK, *Streptococcus pneumoniae* galactokinase; BiGalHexNAcP, *Bifidobacterium infantis* Dgalactosyl-β1–3-*N*-acetyl-D-hexosamine phosphorylase; BfFKP, *Bacteroides fragilis* strain NCTC9343 bifunctional L-fucokinase/GDP-fucose pyrophosphorylase; PmPPA, *Pasteurella multocida* inorganic pyrophosphatase; Hp3/4FT, *Helicobacter pylori* α1–3/4-fucosyltransferase.

Scheme 2.

Synthesizing sLe^aβProN₃ containing different sialic acid forms using one-pot multienzyme (OPME) α2–3-sialylation system containing NmCSS and PmST1 M144D with **(A)** or without **(B)** PmNanA.

Table 1:One-pot multienzyme (OPME) preparative-scale synthesis of sLe^aβProN₃ (6–12).

Entry	Sialic acid or precursor	Product	Yield (%)
a	ManNAc	Neu5Acα2-3Le ^a βProN ₃ (6)	85
b	ManNGe	Neu5Gcα2-3Le ^a βProN ₃ (7)	82
c	Man	Kdnα2-3Le ^a βProN ₃ (8)	86
d	ManNTFA	Neu5NTFAα2-3Le ^a βProN ₃ (9)	80
e	ManNAc6NAc	Neu5Ac9NAcα2-3Le ^a βProN ₃ (10)	76
f	Neu5,9Ac ₂	Neu5,9Ac ₂ α2-3Le ^a βProN ₃ (11)	62
g	Neu5Ge9Ac	Neu5Ge9Acα2-3Le ^a βProN ₃ (12)	51